Oruka (ORKA) Insider Sale of $687K Amid 700% Stock Surge
Published on Β· Source: finance.yahoo.com

AI Summary
Summarized by AI from the source belowArjun Agarwal, Senior Vice President of Oruka Therapeutics (ORKA), sold 9,854 shares for approximately $687,000 on June 12-15, 2026. The shares were sold at a weighted average price of $69.72 after experiencing a nearly 700% increase in stock value. Post-transaction, Agarwal's direct holdings decreased by 36.83%, from 26,753 to 16,899 shares. This transaction follows a notable surge in Oruka's stock driven by positive Phase 2 clinical data indicating 63.5% patient clearance with ORKA-001, creating heightened market interest.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Related News

DB Growth Momentum Targets for 2028 Gain Traction
Sep 25

Abeona Therapeutics stock Buy rating maintained by H.C. Wainwright
Sep 25

Ultragenyx Stock Rating Reiterated by H.C. Wainwright on FDA Approval
Sep 25

Surrozen Stock Target Raised on Wnt Pathway Validation Insight
Sep 25